Zetagen Therapeutics Reports Positive Phase 2a ZetaMet Results
AUSTIN, Texas, June 9, 2026 Zetagen Therapeutics announced preliminary topline results from its Phase 2a clinical study evaluating ZetaMet™...
Metastatic Breast Cancer
Advertisement
Lupin and Natco Win U.S. FDA Approval for Eribulin Injection
MUMBAI, India & NAPLES, Florida, USA, June 3, 2026 Lupin Limited and its alliance partner Natco Pharma have announced...
Avenzo Reports Promising Phase 1 Data for AVZO-021 in HR+ Breast Cancer
SAN DIEGO, Calif., June 1, 2026 Avenzo Therapeutics announced updated clinical results from the Phase 1 portion of its...
Protagonist to Showcase Phase 3 VERIFY and Long-Term Rusfertide Data at EHA 2026
NEWARK, Calif., June 1, 2026 Protagonist Therapeutics announced that four abstracts featuring rusfertide in polycythemia vera (PV) will be...
Biovica’s DiviTum TKa Shows Early Breast Cancer Response Signals
STOCKHOLM, Sweden, May 28, 2026 Biovica, a company focused on blood-based cancer monitoring technologies, announced new translational research published...
Advertisements
Gilead’s Trodelvy Wins CHMP Support in 1L TNBC
FOSTER CITY, Calif., May 25, 2026 Gilead Sciences announced that the European Medicines Agency’s Committee for Medicinal Products for...
Datroway by AstraZeneca Approved as First TROP2 ADC for TNBC
Cambridge, United Kingdom – May 22, 2026 AstraZeneca and Daiichi Sankyo announced that the U.S. Food and Drug Administration...
Rigel Expands Oncology Portfolio With VEPPANU Licensing Deal
SOUTH SAN FRANCISCO, Calif., May 12, 2026 Rigel Pharmaceuticals has entered into an exclusive global licensing agreement with Arvinas...
ALX Oncology Reports Durable HER2 Breast Cancer Data
SOUTH SAN FRANCISCO, Calif., May 7, 2026 ALX Oncology announced promising new clinical findings showing that its investigational CD47...
Totus Medicines Reports Strong Phase 1b Clinical Results for TOS-358 in HR+/HER2- Breast Cancer
EMERYVILLE, Calif., May 6, 2026 Totus Medicines announced encouraging interim Phase 1b clinical data for its investigational therapy TOS-358...
Advertisement
